Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12346712 | 0.94 | PKM (0.48) | PKMMEN1KMT2AGSK3BCDK2 | |
| Trifluoroacetic Acid SCHEMBL2234999 | 0.85 | TSHR (0.43) | KMT2ACXCR3LMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL2238818 | 0.84 | TSHR (0.42) | KMT2ACXCR3LMNA | |
| Trifluoroacetic Acid SCHEMBL2243218 | 0.84 | TSHR (0.42) | KMT2ACXCR3LMNA | |
| Trifluoroacetic Acid SCHEMBL2236181 | 0.84 | BDKRB1 (0.40) | PKMCXCR3LMNA | |
| Trifluoroacetic Acid SCHEMBL1936321 | 0.84 | BDKRB1 (0.40) | PKMCXCR3LMNA | |
| SCHEMBL13495606 | 0.83 | CXCR3 (0.41) | PKMMEN1KMT2ACXCR3SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL2238264 | 0.81 | MAPT (0.37) | MEN1KMT2ACXCR3SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL3263454 | 0.80 | BDKRB1 (0.37) | PKMMEN1KMT2ACXCR3LMNA | |
| Trifluoroacetic Acid SCHEMBL2238388 | 0.80 | ALDH1A1 (0.38) | KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | claimed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | claimed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | PKM 1146/4885MEN1 231/4885KMT2A 1859/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | PKM 1318/4885MEN1 349/4885KMT2A 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.